Investigating how an early form of HIV-1 protease contributes to drug resistance.
Official title: The role of the precursor HIV-1 protease in drug resistance.
Funded at Case Western Reserve University · NIH-11182004 · Data updated 2026-11-12
This study is looking at how a specific form of the HIV-1 protease might help the virus become resistant to medications, which could help us understand why some treatments stop working for people living with HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | January 2, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $507,792 |
| NIH project number | 1R01AI191807-01 |
| Project ID | NIH-11182004 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are experiencing challenges with drug resistance to protease inhibitors.
✕Less likely to help
Patients who are not infected with HIV or those who have not been treated with protease inhibitors may not benefit from this research.
What this research studies
This research focuses on understanding the role of the precursor HIV-1 protease in the development of drug resistance to protease inhibitors. By using innovative techniques to lock the protease in its precursor form, the study aims to explore how this form of the enzyme can lead to mutations that confer resistance to treatment. The research will involve assessing the effects of specific mutations on the protease's function and conducting experiments to observe viral propagation in the presence of these mutations. This could provide valuable insights into how HIV can evade current treatments.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing and overcoming drug resistance in HIV treatment.
How similar studies have gone: Previous research has shown that understanding the mechanisms of drug resistance in HIV can lead to significant advancements in treatment strategies, suggesting that this approach has potential for success.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Tilton, John Christian — Case Western Reserve University
- Study coordinator: Tilton, John Christian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.